You are here
Cancer and economic intelligence
Presentation by Dr. Jean-Jacques Zambrowski at the TAO Congress on 19/20 November 2015
Economic intelligence includes the collection, processing and dissemination of information which is of use to the economic actors, with the aim to produce added value. In France, the use of economic intelligence in healthcare has only just started; health insurance institutions have started to collect and evaluate information and the French National Authority for Health has founded the Commission for Economic Evaluation. Dr. Jean-Jacques Zambrowski discusses the dilemma that medical technology keeps improving and becomes more and more expensive, which – in a context of limited resources – leads to the situation that the most expensive healthcare measures have to be evaluated and confronted with the constraints of economic reality. He reviews the economic aspects of the healthcare system in France, particularly with regard to cancer. Costs associated with illness do not only include the costs of medical care, but also non-medical costs such as transport or household help as well as costs incurred by productivity loss. Dr. Zambrowski also presents the two key indicators for medico-economic evaluation: incremental cost-effectiveness ratio (ICER) and quality-adjusted life year (QALY).
The presentation is followed by a discussion with Isabelle Borget (Health Economist, Institut Gustave Roussy, Villejuif, France) and the audience.
Dr. Jean-Jacques Zambrowski, Université P. Descartes, Paris, France